Guidelines on the management of Waldenström macroglobulinaemia

Br J Haematol. 2006 Mar;132(6):683-97. doi: 10.1111/j.1365-2141.2005.05948.x.
No abstract available

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Cladribine / therapeutic use
  • Drug Therapy, Combination
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Plasma Exchange
  • Prognosis
  • Rituximab
  • Stem Cell Transplantation / methods
  • Thalidomide / therapeutic use
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use
  • Waldenstrom Macroglobulinemia / drug therapy
  • Waldenstrom Macroglobulinemia / immunology
  • Waldenstrom Macroglobulinemia / therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Enzyme Inhibitors
  • Immunologic Factors
  • Immunosuppressive Agents
  • Cladribine
  • Rituximab
  • Thalidomide
  • Vidarabine
  • fludarabine